The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis

The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis

Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiova...

Full description

Saved in:
Bibliographic Details
Main Authors: Yara Dadalti Fragoso, Christian Cardoso Arruda, Walter Oleschko Arruda, Joseph Bruno Bidin Brooks, Alfredo Damasceno, Carlos Augusto de Albuquerque Damasceno, Alessandro Finkelsztejn, Juliana Finkelsztejn, Paulo Diniz da Gama, Maria Cristina Brandão Giacomo, Sidney Gomes, Marcus Vinicius Magno Goncalves, Andre Palma da Cunha Matta, Marilia Manprim de Morais, Enedina Maria Lobato de Oliveira, Yuna Ribeiro, Henry Koiti Sato, Carlos Bernardo Tauil
Format: Article
Language:English
Published: Thieme Revinter Publicações 2014-09-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
esclerose múltipla
fingolimode
bradicardia
evento adverso
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2014000900712&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2014000900712&lng=en&tlng=en

Similar Items